Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – ...

Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...

GRAND RAPIDS, MI, USA I June 20, 2025 I Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by ...

AMSTERDAM, The Netherlands I June 20, 2025 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

Company positioned to initiate multiple Phase 1 clinical trials in 2025 for ART-101 and additional novel radiopharmaceutical assets – ...

HONG KONG, China I June 20, 2025 I Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening ...

SAN DIEGO, CA, USA I June 20, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo ...

BOSTON, MA, USA & CAMBRIDGE, UK I June 19, 2025 I Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction ...

In-vitro lab results confirmed that the Company’s cell targeting nanoparticles successfully entered cancer cells and avoided non-cancerous cells ...

COPENHAGEN, Denmark I June 18, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...